Competition Bureau of Canada investigates generic drug pricing

The Competition Bureau an independent law enforcement agency of Industry Canada recently released a report investigating the pricing and marketing of generic medications in Canada. Their findings were similar to those reported by Brett Skinner of the Fraser Institute several months ago.

The Competition Bureau has concerns that despite strong competition between generic medication manufacturers, the benefits of this competition in the form of reduced cost, is not being passed on to the consumer.

The Canadian Association of Chain Drug Stores strongly disagrees with the Competition Bureau’s conclusion that the benefits of this competition are not reaching the Canadian public in the form of lower prices.

  • Bruce Cran, President of the Consumer’s Association of Canada

Send a Comment

Bitnami